SMAD2 and cardiomyopathy: Here we showed a two- fold increase in circulating TGF-β levels, which is consistent with an increase in phosphorylated Smad-2/3 in the heart tissue, corroborating data found in the cardiac tissue of CD patients with cardiomyopathy [8].